Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart

NCT01846793 is registered in ClinicalTrials.gov with Nymox Corporation as lead sponsor.

NCT NCT01846793
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01846793 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart
Lead sponsor
Nymox Corporation
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2013
Completion date
October 31, 2014
Enrollment
160 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hyperplasia, bph, lower urinary tract symptoms (luts), luts